Cabotegravir–rilpivirine treatment initiation in a nonvirologically suppressed patient-Reference-Cited by-同舟云学术

Cabotegravir–rilpivirine treatment initiation in a nonvirologically suppressed patient

Published:2022-08-01 Issue:10 Volume:36 Page:1475-1476
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Barnett Steven K.,Armas-Kolostroubis Laura,Sension Michael,Riedel David J.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference2 articles.

1. Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials;Rizzardini;J Acquir Immune Defic Syndr,2020

2. Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential;Fernandez;HIV AIDS (Auckl),2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategic use of salvage long-acting antiretrovirals in the setting of resistance;American Journal of Health-System Pharmacy;2024-07-24

2. Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir–Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report;AIDS Research and Human Retroviruses;2024-02-02

3. Early adopters of long-acting injectable cabotegravir/rilpivirine: what lessons can we learn?;AIDS;2024-02-01

4. Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy;Clinical Infectious Diseases;2023-09-22

5. Antiretrovirals;Reactions Weekly;2022-10-01